A compound studied by researchers at the University of California, Berkeley, helped obese mice burn more energy, improve blood sugar regulation and reduce harmful blood fats while largely preserving lean muscle. The molecule, called 5-tetradecyloxy-2-furoic acid (TOFA), increased energy expenditure by as much as 18% without making the animals more active or raising their body temperature. It also enhanced the effects of semaglutide and tirzepatide in mice, although its safety and effectiveness in humans remain unknown.
A different approach to weight loss
Over the past five years, GLP-1 drugs have transformed the treatment of obesity and other metabolic diseases, including diabetes and fatty liver disease. Sold under brand names such as Ozempic, Wegovy, Mounjaro and Zepbound, these drugs have helped many patients lose significant amounts of weight while improving blood sugar regulation.
However, GLP-1 drugs also have limitations. Nausea and other digestive problems can make treatment difficult for some patients. Because the drugs reduce appetite and food intake, they may also increase the risk of nutritional deficiencies and muscle loss. Excessive muscle loss over time can contribute to weakness and other health complications.
The Berkeley researchers investigated a fundamentally different strategy: increasing the amount of energy the body burns instead of relying primarily on reduced food intake.
Energy expenditure includes the calories used to maintain basic bodily functions, regulate metabolism and support daily activities. Increasing it could help people lose weight without relying solely on eating less.
“Weight responds to two levers: eating fewer calories or expending more energy,” said Anders Naar, professor of metabolic biology and nutrition at the University of California, Berkeley, and lead author of the study. “GLP-1 works almost perfectly with the first one, so we considered the second one.”
A compound that burns fat while preserving muscle
The researchers focused on TOFA, a molecule with an unusual combination of effects on metabolism.
TOFA interferes with the production of lipids, a broad category of fatty substances that includes cholesterol and triglycerides. Although lipids perform important functions in the body, excessive levels of certain types can contribute to metabolic disorders and cardiovascular disease.
At the same time, TOFA activates genes involved in taking in and burning fat for energy. This allows the compound to influence both how the body produces fat and how it uses fat as fuel.
In experiments on mice, TOFA improved insulin sensitivity. Insulin helps move glucose from the bloodstream into cells, so greater sensitivity makes it easier for the body to regulate blood sugar. This could be relevant to diabetes and insulin resistance.
The compound also lowered triglyceride levels and improved features of fatty liver disease, a condition in which excess fat accumulates in liver cells and can eventually interfere with liver function.
Most notably, obese mice treated with TOFA lost weight primarily through reductions in body fat, without significant losses of lean muscle mass. Preserving muscle may be important for maintaining strength, mobility and long-term metabolic health.
How TOFA increased energy expenditure
TOFA was first discovered in the 1970s, but the new research identified additional properties that could be useful in treating metabolic diseases.
The compound belongs to a group known as ACC inhibitors. These compounds interfere with enzymes involved in fatty-acid production, slowing the synthesis of certain fats.
Other ACC inhibitors have reached mid-stage clinical trials, but none has been approved to treat metabolic diseases. One major challenge is the possibility of unexpected side effects. Many ACC inhibitors can increase blood triglyceride levels, potentially raising the risk of heart disease.
The Berkeley team found that TOFA does more than inhibit ACC. It also activates two cellular receptors, PPARα and PPARδ, which regulate genes involved in fat metabolism.
These receptors act as molecular switches. When activated, they stimulate processes that allow cells to absorb and break down fatty acids to produce energy. As a result, TOFA reduces the production of certain fats while increasing the burning of fats already available to the body.
In mice, this activity increased energy expenditure by as much as 18% without requiring additional physical activity or raising body temperature. Unlike other ACC inhibitors, TOFA did not increase triglyceride levels, possibly because of its additional effects on fat metabolism.
“TOFA appears to trigger a coordinated metabolic response,” said Justin Y. Lee, a postdoctoral fellow at the University of California, San Francisco, who conducted the research as a Ph.D. student at Berkeley and was the study’s lead author. “It doesn’t just block lipid synthesis; it also activates energy-consuming pathways and may help the body process excess lipids and glucose more effectively.”
To determine whether the same effects could be achieved with separate treatments, the researchers gave mice a combination of two different compounds: one that blocked lipid production and another that stimulated energy expenditure.
Surprisingly, the two-compound treatment was less effective than TOFA alone at improving overall metabolic health. The result suggests that TOFA’s ability to influence multiple metabolic processes through a single molecule may be an important part of its effect.
Could TOFA complement Ozempic and Wegovy?
The researchers also tested whether TOFA could improve the effects of existing GLP-1 treatments.
They administered the compound alongside semaglutide, the active ingredient in Ozempic and Wegovy, and tirzepatide, which is sold as Mounjaro and Zepbound.
These drugs primarily promote weight loss by reducing appetite and food intake. TOFA targets the other side of the energy-balance equation by increasing the amount of energy the body expends.
When the researchers combined TOFA with the drugs in mice, the results were more favorable than those achieved with either treatment alone. The combinations significantly improved body weight, blood sugar regulation, insulin levels and triglycerides.
The findings suggest that treatments targeting calorie intake and energy expenditure could potentially work together to produce stronger metabolic effects.
“In our combination experiments, TOFA acted additively or synergistically with GLP-1 appetite suppressants, so we consider them complementary rather than substitutes,” Naar said.
Researchers do not necessarily envision TOFA replacing drugs such as Ozempic or Wegovy. Instead, it could eventually serve as an additional treatment for obesity and related metabolic conditions through a different biological mechanism.
Human trials are still needed
Despite the promising results, TOFA remains an experimental compound. The findings so far come from animal studies, and its safety and effectiveness in humans have not been established.
Further research is needed to determine whether similar metabolic improvements can be achieved in humans and whether TOFA offers meaningful advantages over existing treatments.
To pursue potential clinical applications, Berkeley scientists have formed a biotechnology company called ReRx Therapeutics. The effort is supported by the university’s Life Sciences Entrepreneurship Network, including Nucleate and Berkeley SkyDeck.
If the findings can ultimately be translated to humans, TOFA could become an addition to treatments for obesity and diabetes. Its potential significance lies in encouraging the body to use more energy while helping preserve muscle during weight loss.
The study was funded through discretionary resources provided by the University of California, Berkeley, with additional support from the University of California, San Francisco Liver Center and the University of Michigan Animal Phenotyping Core.
Other authors included Chi Zhu, Melissa A. Boldridge, Rachelle L. Stark, Lei Xu, Federico Gonzalez, Xin Tang, Kaitlyn T. Dang and Kook Son of Berkeley; Gracia Bonilla, Kashish Chetar and Ruslan I. Sadlev of Massachusetts General Hospital; Kosuke Watari and Michael Karin of the University of California, San Diego; Christina Papa and Bilal N. Shaikh of the Munich Helmholtz Center; and Prabha Ibrahim of ReRx Therapeutics.
Source: www.sciencedaily.com












